Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1988-8-17
|
pubmed:abstractText |
In Type II, non-insulin-dependent diabetes, insulin secretion is often reduced to the point where oral hypoglycaemic agents fail to control the plasma glucose level. We studied 12 patients (age 41-66 years; 4 lean, 8 obese) with Type II diabetes mellitus for 1-25 years who were uncontrolled despite maximal dose glibenclamide and metformin. After withdrawal of medication, blood glucose control was determined by measuring glucose before and 2 h after each meal for 48 h, and beta-cell function by insulin or C-peptide response to glucagon and to iv glucose. Following these tests, intensive insulin treatment (CSII) was initiated, and near-euglycaemia (mean of 7 daily glucose determinations less than 7.7 mmol/l) was maintained for 16.6 +/- 1.5 days, at which time the tests were repeated. Mean daily insulin requirement was 61 +/- 9 IU (0.81 +/- 0.09 IU/kg). Glucose control was improved after cessation of CSII (mean glucose 12.7 +/- 0.6 mmol/l after vs 20 +/- 1.5 mmol/l before, P less than 0.005). Maximum incremental C-peptide response improved both to glucagon (214 +/- 32 after vs 134 +/- 48 pmol/l before, P = 0.05) and to glucose iv bolus injection (284 +/- 53 vs 113 +/- 32 pmol/l, P less than 0.05). Peak insulin response, measured after iv glucose infusion, also tended to be higher in the post-CSII test (42 +/- 18 vs 22 +/- 5.6 mU/l). Basal and stimulated proinsulin concentrations were high relative to C-peptide levels during the pre-treatment period, but returned to normal after CSII.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/C-Peptide,
http://linkedlifedata.com/resource/pubmed/chemical/Glucagon,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin,
http://linkedlifedata.com/resource/pubmed/chemical/Proinsulin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0001-5598
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
118
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
365-73
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3293339-Adult,
pubmed-meshheading:3293339-Aged,
pubmed-meshheading:3293339-Blood Glucose,
pubmed-meshheading:3293339-C-Peptide,
pubmed-meshheading:3293339-Diabetes Mellitus, Type 2,
pubmed-meshheading:3293339-Female,
pubmed-meshheading:3293339-Glucagon,
pubmed-meshheading:3293339-Glucose Tolerance Test,
pubmed-meshheading:3293339-Humans,
pubmed-meshheading:3293339-Insulin,
pubmed-meshheading:3293339-Insulin Infusion Systems,
pubmed-meshheading:3293339-Islets of Langerhans,
pubmed-meshheading:3293339-Male,
pubmed-meshheading:3293339-Middle Aged,
pubmed-meshheading:3293339-Proinsulin
|
pubmed:year |
1988
|
pubmed:articleTitle |
Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes.
|
pubmed:affiliation |
Department of Endocrinology and Metabolism, Hebrew University Hadassah Medical Center, Jerusalem, Israel.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|